Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy

The 2019 coronavirus disease (COVID-19) is the disease caused by SARS-CoV-2 infection. Although this infection has been shown to affect the respiratory system, a high incidence of thrombotic events has been observed in severe cases of COVID-19 and in a significant portion of COVID-19 nonsurvivors. A...

Full description

Saved in:
Bibliographic Details
Published in:American journal of physiology. Heart and circulatory physiology 2022-01, Vol.322 (1), p.H87-H93
Main Authors: Seth, Ryan, McKinnon, Thomas A J, Zhang, X Frank
Format: Article
Language:English
Subjects:
ADAM protein
ADAMTS13 Protein - metabolism
Blood Coagulation
Blood Coagulation Disorders - etiology
Blood Coagulation Disorders - metabolism
Coagulation
Coronaviruses
COVID-19
COVID-19 - blood
COVID-19 - complications
Humans
Infections
Inflammation
Respiratory system
Severe acute respiratory syndrome coronavirus 2
Thrombospondin
Viral diseases
Von Willebrand factor
von Willebrand Factor - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The 2019 coronavirus disease (COVID-19) is the disease caused by SARS-CoV-2 infection. Although this infection has been shown to affect the respiratory system, a high incidence of thrombotic events has been observed in severe cases of COVID-19 and in a significant portion of COVID-19 nonsurvivors. Although prior literature has reported on both the coagulopathy and hypercoagulability of COVID-19, the specifics of coagulation have not been fully investigated. Observations of microthrombosis in patients with COVID-19 have brought attention to potential inflammatory endothelial injury. Von Willebrand factor (VWF) and its protease, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13), play an important homeostatic role in responding to endothelial injury. This report provides an overview of the literature investigating the role the VWF/ADAMTS13 axis may have in COVID-19 thrombotic events and suggests potential therapeutic strategies to prevent the progression of coagulopathy in patients with COVID-19.
ISSN:0363-6135
1522-1539
DOI:10.1152/AJPHEART.00204.2021